Start-up Profile

Founded: 2018

Country: United Kingdom

Number of employees: 8

Main focus areas/active in: 

  • Production Processes
  • Biosurfactants

Investors: ICOS capital

Website: www.holiferm.com

Follow us:

Which input provides your business model/core technology towards a bio-based economy?

Holiferm’s technology facilitates the replacement of petrochemically derived surfactants with fermentation derived surfactants whilst maintaining or improving the cost performance ratio.

Which market/clients do you address and which short-/long-term goals do you have?

We provide clients with biosurfactants which can be more effective than traditional surfactants on a price:performance basis, as well as the expected mildness and green claims. In the short term we plan to launch sophorolipids onto the market, with 2 tonnes/month expected in Q1 2021, and plans for a 1200 tonne commercial plant operational by 2023 and a 20 000 tonne plant operational around 2025. Long term, we plan to launch a wide range of biosurfactants we have brought to a comparable cost price with existing surfactants using our ‘Gravisep’ technology, whilst expanding to building low cost production and integrated separation processes for a broad range of fermentation derived lipids.

What makes your approach unique compared to other stakeholders in this field?

Holiferm has a unique approach in that we recover the biosurfactants from the fermentation broth as they are produced. This debottlnecks the process, enabling us to produce 3-4x more from a given plant compared to the state of the art, and reduces the production cost by around 50%. This enables Holiferm to market biosurfactants at typical speciality surfactant price points, rather than the niche prices currently seen in the biosurfactant market. Holiferms technology is applicable to a wide range of biosurfactants and other lipid products.

Get in touch!

Ben Dolman

Please fill out the form below to get in touch with us.